Skip to main content
Midas Edge

Janux Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 8, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 8, 2024

JANX$12.76-27.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Statements of Stockholders’ Equity

(in thousands, except share data)

Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’
Shares · Amount · Capital · Income (Loss) · Deficit · Equity
Balance at December 31, 202141,243,137$41$413,967$(270)$(47,411)366,327
Exercise of common stock options7,405—1——1
Shares issued under employee stock purchase plan54,299—499——499
Vesting of restricted shares311,41911,033——1,034
Stock-based compensation——17,203——17,203
Unrealized loss on available-for-sale securities, net———(1,265)—(1,265)
Net loss————(63,059)(63,059)
Balance at December 31, 202241,616,260$42$432,703$(1,535)$(110,470)$320,740
Issuance of common stock and pre-funded common stock warrants, net of issuance costs4,153,717456,526——56,530
Exercise of pre-funded common stock warrants80,257—————
Exercise of common stock options253,545—2,246——2,246
Shares issued under employee stock purchase plan90,574—772——772
Vesting of restricted shares58,087—149——149
Stock-based compensation——20,005——20,005
Unrealized gain on available-for-sale securities, net———2,200—2,200
Net loss————(58,293)(58,293)
Balance at December 31, 202346,252,440$46$512,401$665$(168,763)$344,349
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.